Fludarabine + Busulfan + Low-dose TBI conditioning regimen

Current understanding

To be populated as evidence accumulates.

2026-05-15 — Prospective Single-Arm Clinical Study of Thiotepa-Containing Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Chronic Myelomonocytic Leukemia: cross-connection with thiotepa-busulfan-fludarabine-conditioning-cmml: Alternative intensification strategy to FluBu (thiotepa-based alkylator augmentation vs. low-dose TBI augmentation) for high-risk myeloid disease conditioning. (novelty: 3)
2026-04-03 — Fludarabine and Busulfan vs. Fludarabine, Busulfan and Total Body Irradiation: Trial-early: experimental arm in a randomized single-institution trial testing whether adding low-dose TBI to FluBu reduces relapse without increasing transplant-related toxicity in allo-SCT for myeloid malignancies including MPNs. (novelty: 3)